Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kaiting Tang"'
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 8, Pp 648-654 (2024)
Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies. Chimeric antigen receptor (CAR) T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical re
Externí odkaz:
https://doaj.org/article/356ab3a80d3b45df983e66a0bbd94215
Autor:
Shiyu Zuo, Chuo Li, Xiaolei Sun, Biping Deng, Yibing Zhang, Yajing Han, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Jiao Zong, Zhenglong Tian, Lingling Shan, Kaiting Tang, Huifang Huang, Yanzhi Song, Qing Niu, Dongming Zhou, Sizhou Feng, Zhongchao Han, Guoling Wang, Tong Wu, Jing Pan, Xiaoming Feng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Chimeric antigen receptor (CAR) T cells show suboptimal efficacy in acute myeloid leukemia (AML). We find that CAR T cells exposed to myeloid leukemia show impaired activation and cytolytic function, accompanied by impaired antigen receptor
Externí odkaz:
https://doaj.org/article/44e53ade52754034b066beff90fa2b1b
Publikováno v:
ImmunoMedicine, Vol 2, Iss 1, Pp n/a-n/a (2022)
Abstract In recent years, CD19‐directed chimeric antigen receptor (CAR) T cell therapy has exhibited significant potency for treating pediatric relapsed or refractory B‐cell acute lymphoblastic leukemia (r/r B‐ALL). Nonetheless, many patients w
Externí odkaz:
https://doaj.org/article/7c32e539abfc46c3af9a857bd7983c64
Autor:
Jiajia Duan, Qinlong Zheng, Xinjian Yu, Fangrong Yan, Biping Deng, Xiaoming Feng, Alex H. Chang, Yue Tan, Zhenglong Tian, Jinlong Xu, Weiliang Song, Jiecheng Zhang, Xiuwen Xu, Kaiting Tang, Ying Yuan, Guoling Wang, Zelin Wang, Yanlei Zhang, Shuixiu Peng, Jing Pan, Zhuojun Ling, Samuel Seery
Publikováno v:
Journal of Clinical Oncology. 39:3340-3351
PURPOSEPatients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell safety and efficacy in patients with
Autor:
Liping Zhao, Jing Pan, Kaiting Tang, Yue Tan, Biping Deng, Zhuojun Ling, Weiliang Song, Alex H. Chang, Xiaoming Feng
Publikováno v:
Journal of Clinical Oncology. 40:7035-7035
7035 Background: Refractory or relapsed (r/r) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) has a poor prognosis. Our previous report showed that donor-derived CD7 CAR-T cell therapy could induce remission of r/r T-ALL, but graft-versus-ho